Previous research has shown aberrant expression patterns of NIR1 in numerous types of tumors including breast cancer, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) [18–20]. Here, PITPNM3 is linked to breast carcinoma.